Deuterated psilocybin - Lennham Pharmaceuticals
Alternative Names: D-Psilocybin - Lennham Pharmaceuticals; Psilocybin - Lennham PharmaceuticalsLatest Information Update: 02 Jun 2022
At a glance
- Originator Lennham Pharmaceuticals
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 31 May 2022 Lennham Pharmaceuticals has patent protection for methods of using psilocybin and psilocin in an MAO-A deficient patient population in USA
- 12 Sep 2021 Lennham Pharmaceuticals has patents pending for methods of using psilocybin and psilocin in USA
- 01 Sep 2021 Deuterated psilocybin is available for licensing as of 01 Sep 2021. https://www.lennham.com/